Promega's HDAC-Glo bioluminescent assays are designed for the measurement of the relative activities of histone deacetylases (HDAC) for basic research, screening and drug discovery.
The HDAC-Glo and SIRT-Glo assays and screening systems use a single-reagent-addition, add-mix-measure protocol for easy implementation in benchtop to high-throughput screening applications, reducing labour and time to results.
The company claimed the systems speed up data acquisition times and provide 10- to 100-fold higher sensitivity than comparable fluorescence assays.
HDACs are key epigenetic regulators of gene transcription and an important new target class of enzymes in drug discovery epigenetics programmes aimed at therapeutic areas such as oncology, metabolic disease, aging and neurological disorders.
The HDAC-Glo assay is useful for class I and II HDAC enzymes in cells, cell extracts, or purified enzyme; the SIRT-Glo assay is useful for NAD+ dependent class III HDAC purified enzymes (sirtuins or SIRTs).
The assays use Promega's Ultra-Glo recombinant firefly luciferase technology in an add-mix-measure format where the amount of light produced correlates to HDAC enzyme activity.
The assays have broad linearity and high sensitivity minimising the amount of enzyme required and improving the limits of detection for screening applications.
They are completed in 15-45 minutes and produce a signal half-life greater than three hours, allowing for batch processing of multi-well assay plates.
The cell-based HDAC-Glo Assay enables multiplexed viability assays to be performed for applications such as scaffold profiling or target-specific potency evaluation.
